What Uniferol Treats: Main Uses and Benefits

Correction of Deficiency-Related Anemia and Fatigue

Uniferol is commonly used to address Folic Acid deficiency states, particularly when this leads to the condition known as megaloblastic anemia (a type of macrocytic anemia). Folic Acid is a B vitamin considered relevant in clinical settings that involve nutritional support. This use addresses groups of systemic symptoms that create noticeable physiological strain, such as profound fatigue, debilitating lack of energy, and overall weakness. The medication is applicable across conditions presenting with deficiency-related neurological and mucosal symptoms, including paresthesia and mouth ulcers. Providing this supportive therapeutic benefit contributes to easing the overall symptom load associated with deficiency, assisting patients in coping more steadily with the difficult, chronic burden of these manifestations.

“This preparation is generally used in clinical settings that involve nutritional imbalances and conditions characterized by systemic imbalance and deficiency.”

---

Essential Prophylaxis and Supportive Management

The medication is considered relevant for women of childbearing age and those planning to conceive due to its role in supporting the reduction of risk for major congenital anomalies. This high-level preventative measure provides a key therapeutic benefit during the critical periconceptional period. Uniferol is also applied as supportive care for patients with malabsorptive disorders or those undergoing long-term dialysis, as well as individuals requiring supplementary measures to counteract folate depletion caused by specific necessary medications.

Quick Fact: Relief for Systemic Fatigue and Neurological Symptoms related to Folic Acid deficiency.

Regulatory References

1. NIH MedlinePlus overview of Folic Acid

Eligibility Scope

Category	Regulatory Status	Description
Populations Allowed	Permitted/Recommended	Includes all adults, the pediatric population (children and infants), and pregnant/breastfeeding women for the treatment of deficiency and prophylaxis. [DailyMed]
Conditional Use	Caution/Restriction	Applies to patients with chronic hemolytic states, malabsorptive disorders, or those undergoing renal dialysis. Use in older adults for long-term therapy is conditional on first ruling out Cobalamin deficiency. [NHS UK]
Contraindicated	Absolutely Prohibited	Patients with Untreated Cobalamin (Vitamin B12) Deficiency, including pernicious anemia, must not use Uniferol, as the drug can mask the hematological signs while allowing irreversible neurological damage to advance. [DailyMed]
Other Exclusions	Contraindicated	Patients with known Hypersensitivity to Folic Acid or any of the product's excipients are excluded. Use in patients with malignant disease is restricted unless the megaloblastic anemia is specifically due to folate deficiency. [emc]

Age-Related Eligibility: Folic Acid is generally considered appropriate across all age groups from infancy through older adulthood. The regulatory status for pregnant women is established as permitted and recommended (Pregnancy Category A) for both the correction of deficiency and fetal prophylaxis.

Connection to the overall eligibility profile: Official documents establish who may use the medicine by broadly permitting its use in deficiency states across the lifespan while setting strict safety boundaries. The eligibility profile is primarily structured around mitigating the risk of administering the drug alone in the presence of an undiagnosed or untreated Vitamin B12 deficiency.

Interactions with other medicines and products

The official interaction profile of Uniferol (Folic Acid) documents clinically relevant interaction patterns with several medicinal product categories and substances.

Interaction Scope

Category	Official Regulatory Information
Medicinal product categories with documented interactions	Folate antagonists (e.g., Methotrexate), Anticonvulsants (e.g., Phenytoin), Antibiotics (e.g., Chloramphenicol, Tetracycline).
Specific interacting medicines (if explicitly listed)	Methotrexate, Phenytoin, Phenobarbital, Primidone, Chloramphenicol, Tetracycline.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic antagonism, reduced serum levels of co-administered drugs, and transporter interaction.
Timing-based interaction rules (if applicable)	None explicitly written as a mandatory administration-timing rule in the regulatory label.
Population-specific interaction notes (if applicable)	Epileptic patients whose condition is controlled by anticonvulsants may require increased doses of the anticonvulsant to maintain seizure control.

Interaction Classifications (High-Level)

Category	Official Regulatory Information
Interaction severity classification (as defined in official documents)	Described as clinically relevant for specific drug classes (anti-epileptics, anti-folates).
Interaction-context constraints (as defined in official documents)	Caution regarding potential loss of seizure control in previously stabilized epileptic patients is documented.

Resulting Interaction Structure

Official interaction statements:

• Folic Acid may decrease the therapeutic responses to the anti-folate medicine Methotrexate.
• Co-administration is associated with a reduction in the serum levels of certain anticonvulsant medicines, including Phenytoin.
• The antibiotic Chloramphenicol is documented to exert a pharmacodynamic antagonism on Folic Acid's therapeutic effects.
• Alcohol consumption is noted to interfere with Folic Acid metabolism.
• Green Tea is documented to decrease Folic Acid's bioavailability via a folate transporter interaction.

Connection to the overall interaction profile (3 sentences):

The official interaction structure is defined by the risk of antagonizing the effects of anti-folate agents and the potential for reducing the exposure of certain co-administered anticonvulsants. The profile further includes specific documentation of non-medicinal substances, such as alcohol and Green Tea, which can affect Folic Acid's metabolism or transporter-mediated availability. This structure formally acknowledges specific interactions across therapeutic and lifestyle categories, focusing solely on the reported outcomes documented in government labeling.

The mechanism of Uniferol (Folic Acid) is purely biochemical, functioning as a precursor to essential cofactors rather than modulating receptor activity.

The Role of Uniferol as a Metabolic Cofactor

Folic Acid is reduced by enzymes like Dihydrofolate Reductase (DHFR) into active tetrahydrofolate (THF) derivatives. These derivatives act as essential substrate donors within the cellular one-carbon metabolic pool. This mechanism directly replenishes C1 units required for cellular machinery, targeting key C1 unit transfer enzymes.

Fueling DNA Synthesis and Replication

The coenzymes operate within the DNA Synthesis Pathway to support the formation of Purines and the pyrimidine, dTMP, by providing the necessary C1 units. This pathway modulation facilitates DNA replication and nuclear maturation in rapidly dividing cells.

Supporting Hemopoietic Proliferation and Maturation

This molecular cascade translates systemically into support for the Hemopoietic System. The facilitation of accurate DNA production supports the proliferation and maturation of red blood cell precursors within the bone marrow. This mechanism contributes to the formation and release of mature blood cells into the systemic circulation.

Why the Mechanism is B12-Dependent

The mechanism is constrained by a metabolic interdependence on Vitamin B12 (Cobalamin). If B12 is absent, Folic Acid intermediates become metabolically trapped, establishing a physiological constraint on the action by impairing participation in DNA synthesis.

Administration Routes and Forms

Uniferol (Folic Acid) is primarily administered via the oral route, utilizing available tablets or liquid solutions. This is the preferred method for routine supplementation and maintenance therapy. However, when a patient presents with severely impaired gastrointestinal absorption or other clinical necessities, specialized parenteral forms are available for administration. These injectable forms can be delivered via the intramuscular (IM), intravenous (IV), or subcutaneous (SC) routes, typically reserved for use under clinical supervision.

---

Dosing Patterns and Frequency

The dosage schedule for Folic Acid is segmented according to its intended use. For routine prophylaxis in specific patient groups, the dose is commonly 400 mcg once daily. In cases requiring therapeutic correction of an established deficiency, the typical dose range for adults extends from 1 mg up to 5 mg daily, depending on the severity of the deficiency state. Administration is generally a once-daily pattern. While deficiency treatment may involve a short-term course (e.g., up to four months), preventative use often requires continuous daily intake throughout the at-risk period.

---

Key Procedural Requirements

Folic Acid tablets can be taken with or without food and should be swallowed whole with water. A critical procedural constraint governs the use of higher daily doses: administration exceeding 0.1 mg per day must not be initiated unless the underlying cause of the megaloblastic anemia has been determined or simultaneous treatment for potential Vitamin B12 deficiency has been established. This is a necessary step to ensure appropriate use and procedural compliance.

Research Evidence / Overview of Studies

Phase I: Initial Safety and Pharmacokinetics

The earliest stage of research focused on understanding how the drug is absorbed, distributed, metabolized, and eliminated (pharmacokinetics or PK) and establishing its initial safety profile.

• PK/PD Analysis: Research explored the compound's characteristics, focusing on inhibition of a specific receptor pathway. Initial small-scale studies evaluated the compound’s association with inflammation markers.
• Safety Profile: The safety profile was assessed in most adults during the trial period. Adverse events reported were typically mild and self-limiting.

---

Phase II: Efficacy and Dose-Ranging Trials

Phase II trials were conducted in a larger group of participants to gather preliminary information on potential effects and to establish the dosage range used in later studies.

• Symptom Change Study: One study evaluated the change in the severity of acute flare-ups over a period of 12 weeks. Researchers examined the impact of this agent in participants with moderate to severe symptoms.
• Combination Treatment: Research evaluated whether the combination of both components influences pain perception. This component was also studied for its impact on sleep quality, with mixed findings reported across different studies.

---

Phase III: Large-Scale Confirmatory Trials

Phase III involved large, multi-center studies designed to confirm preliminary findings and assess long-term observations.

• Primary Efficacy Trial (Study 301): This was a 52-week, double-blind, placebo-controlled trial. The study’s primary endpoint was the change in a specific clinical severity index. Study findings indicated that participants in the treatment group had a statistically significant difference in flare-ups compared to placebo.
• Onset-of-Action Study: In a Phase III trial, researchers studied the onset of action and reported a change in acute symptoms.
• Comparative Trial: One trial compared the agent's effects to those of an existing treatment. Results indicated that both agents were associated with a similar effect on the primary endpoint.

---

Post-Marketing Studies and Real-World Evidence

Ongoing observational studies continue to monitor the long-term safety profile and participant outcomes in a broader, more diverse population.

• Patient Compliance Study: The dose-ranging study observed rates of adherence to the study protocol over six months.
• Discontinuation Studies: (Information related to the observation of discontinuation was collected in trials.)

Common questions about Uniferol (FAQ)

Q: Are the common side effects of Uniferol generally temporary?

Regulatory summaries indicate that the adverse events reported during initial studies were typically mild and were described as self-limiting. This suggests that if side effects occur, they are generally temporary and resolve on their own. The full safety section contains a comprehensive understanding of all possible effects.

Q: Are there any specific vitamin or herbal supplements known to interact with Uniferol?

Official product information indicates that Folic Acid may interact with certain substances, including Zinc supplements and antacids that contain aluminum or magnesium. Additionally, the consumption of Green Tea is documented to affect Folic Acid's availability in the body. The full interactions section provides a complete list of known substance interactions.

Q: Can Uniferol be used by older adult patients (senior population)?

Uniferol (Folic Acid) is permitted for use across all age groups, including older adults. However, for long-term use in this population, regulatory guidance states it is necessary to first rule out a Vitamin B12 deficiency to align with regulatory standards for use. This condition can be masked by Folic Acid if it is not addressed.

Q: How often do the more serious side effects of Uniferol occur?

According to official safety information, adverse reactions—including serious hypersensitivity reactions such as anaphylaxis—are classified as rare. The overall safety profile of Folic Acid is characterized by a low incidence of direct adverse effects documented in regulatory labeling.

Q: Do lifestyle factors like smoking or caffeine intake impact Uniferol's effectiveness?

Regulatory documents specifically note that alcohol consumption interferes with how the body processes Folic Acid. Furthermore, Green Tea is documented to interact with the mechanism that helps transport the substance into the body. No official statements are made in regulatory documents regarding smoking or other general caffeine sources.

Q: Is it common to feel slightly ill when first starting Uniferol?

While official documentation lists symptoms like nausea, flatulence, and general discomfort (malaise), these effects are generally classified as rare for Folic Acid. The full safety section should be consulted for a comprehensive list of effects.

Q: Are there any food types, besides alcohol, that are officially listed as drug interactions?

Yes, the official interaction profile includes Green Tea as a substance that may decrease the availability of Folic Acid via a folate transporter interaction. This is noted alongside alcohol as a documented non-medicinal substance that can interfere.

Q: How quickly does Uniferol begin to wear off after the last dose?

Studies reviewed by regulatory bodies include analysis of the drug's pharmacokinetics. This process involves how quickly the body absorbs, distributes, metabolizes, and eliminates (wears off) the substance, which helps determine the appropriate administration frequency.

Q: Is the mechanism of action of Uniferol fully understood by scientists?

Regulatory sources describe the mechanism in detail, explaining that Folic Acid is transformed into cofactors essential for DNA synthesis and cell division. This established biochemical process forms the official basis for its therapeutic effect.

Q: Is the generic form of Uniferol considered as effective as the brand-name version?

Regulatory agencies like the FDA require that generic formulations of Folic Acid must demonstrate bioequivalence to the brand-name version. Bioequivalence means that the generic drug is absorbed into the bloodstream at the same rate and extent as the original product.

Q: Does Uniferol affect a patient’s ability to drive or operate machinery?

Official prescribing information indicates that Folic Acid is expected to have no or negligible influence on a patient's ability to drive a vehicle or operate machinery under normal therapeutic use.

Q: Can Uniferol be taken by individuals who are already taking blood thinners?

When checking official drug interaction databases, Folic Acid typically shows no documented interaction with the common blood thinner medication, warfarin. The comprehensive interactions section should be consulted by patients taking any blood thinners.

Q: What should a patient know if they are considering stopping Uniferol?

Authoritative patient guidance advises that cessation of use of Uniferol is typically determined by a healthcare provider. This is standard advice for maintaining treatment efficacy and safety, particularly for conditions requiring continuous support.

Q: Does Uniferol have known interactions with common over-the-counter pain relievers?

According to regulatory-backed patient information, Folic Acid can generally be taken simultaneously with the common painkiller Paracetamol. Caution is noted when taking NSAIDs (like ibuprofen) if the patient is also taking the anti-folate drug Methotrexate.

Q: What is the relationship between Uniferol and liver function?

Authoritative reports indicate that Folic Acid intake, even at doses higher than typically used, is not associated with liver injury or the presence of liver test abnormalities. This information is derived from comprehensive safety reviews.

Q: What does the patient information leaflet say about missed doses of Uniferol?

Standard patient information describes the general guidance for a missed dose as taking it when remembered, but only if it is not close to the time for the next scheduled dose. If it is almost time for the next dose, the guidance is to resume the regular schedule.

Q: What happens if a patient takes Uniferol for longer than the prescribed duration?

Long-term, continuous daily intake is an expected pattern of use for preventative purposes. Official documents only associate potential Central Nervous System effects, such as confusion or irritability, with the chronic administration of very high doses (those far exceeding standard therapeutic use).

Storage and Handling

Official regulatory guidelines for similar vitamin-based products generally require storage at controlled room temperature, away from excess heat and moisture. To maintain product stability, the medication should be kept in its original container with the lid tightly closed when not in use. Patients are instructed to protect the medication from light, which can degrade the active ingredient over time.

Storage Requirement	Standard Guidance
Temperature	Controlled Room Temperature
Protection	Keep in Original Container, Protect from Light and Moisture
Children's Access	Store Out of Sight and Reach of Children

Disposal Instructions

Unused or expired medication should not be disposed of by flushing down the toilet or pouring down a drain unless specifically instructed by a medical professional or a drug take-back program. Instead, patients should follow local regulations and utilize community drug take-back programs or consult with a pharmacist for proper disposal methods. This practice ensures safe handling and prevents environmental contamination.